A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers

Liu, Man; Xing, L.J.; Liu, Yi-Jing

doi:10.1097/md.0000000000006222

Cited by 63 publications

(61 citation statements)

References 40 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LncRNAs were considered as non-protein-coding transcripts longer than 200 nucleotides and widely expressed in various organs and tissues of the body [14-16]. Functional lncRNA was involved in various cancer biological processes, such as proliferation, apoptosis, invasion and metastasis through modulation of chromatin remodeling, epigenetics modification, regulation of gene transcription, post-transcriptional mRNA processing, protein function and localization, and intercellular signal transduction regulation [17].…”

Section: Introductionmentioning

confidence: 99%

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

Yuan¹,

Sun²,

Liu³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circulating (serous or plasmic) long non-coding RNA (lncRNA) as biomarkers for predicting the diagnosis or prognosis of human disease have been well documented. Due to the sensibility or specificity limitation of Alpha Fetoprotein (AFP), a cluster lncRNAs were revealed as fingerprints for hepatocellular carcinoma (HCC). In this study, we enrolled all the reported circulating lncRNAs in HCC as candidate targets and examined in an independent cohort. Methods: The candidate lncRNAs were determined by qRT-PCR divided into training and validation sets. The risk score analysis was employed to evaluate the potential diagnosis ability of the lncRNAs independently or combining with AFP value. The receiver operating characteristic curve (ROC) was applied for presentation of sensibility or specificity. Results: Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls. The risk score analysis revealed the combination of three lncRNAs with AFP could distinguish the HCC from either CH or healthy control with the area under curve value (AUC) of 0.986 and 0.985, respectively. Conclusion: The three lncRNAs may act as novel biomarkers for acting as fingerprint in HCC combining with AFP.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

Yuan¹,

Sun²,

Liu³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Therefore, simultaneous evaluation of tumour‐associated circulating lncRNA panel may increase the sensitivity and specificity of diagnosis and prognosis in breast cancer. Towards this direction, one recent study using a small cohort has demonstrated that a three‐lncRNA signature, including ANRIL, HIF1A‐AS2 and UCA1, can serve as diagnostic markers for differentiating between triple‐negative and non‐triple‐negative breast cancer . Evidently, further systematic and multicenter studies of larger independent samples are urgently needed to develop the possible clinical applications of circulating lncRNAs in patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

The oncogenic potentials and diagnostic significance of long non‐coding RNA LINC00310 in breast cancer

Peng

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Recent studies have revealed that long non‐coding RNAs (lncRNAs) are involved in different physiological processes and human diseases. However, to date, the function and overall clinical significance of the vast majority of lncRNAs in breast cancer remain largely unexplored. Here, we focused on LINC00310 by interrogating the breast invasive carcinoma data set of the Cancer Genome Atlas (TCGA). The results showed that LINC00310 was increased as breast cancer progressed, and the deregulation of LINC00310 was significantly associated with patients’ survival. Experiments with knockout (KO) approach by CRISPR/Cas9 system and the subsequent rescue experiments revealed that LINC00310 promoted cell proliferation by regulating c‐Myc expression in vitro. Nude mouse xenograft assay demonstrated that LINC00310 KO significantly suppressed tumour growth in vivo. Furthermore, we found that serum LINC00310 expression was significantly up‐regulated in patients with breast cancer, and receiver operating characteristic (ROC) curve analysis indicated that LINC00310 had a powerful capability of distinguishing patients with breast cancer from healthy individuals (the area under curve 0.828). Taken together, these results provide a more intuitive approach to explore the clinical relevance and functional roles of lncRNAs. As a result, lncRNAs, such as LINC00310, may be used in clinical applications as circulating markers for breast cancer.

show abstract

“…In addition, it has been found that lncRNAs may be expressed either ubiquitously or in a tissue-specific manner [39] and that they may be released in a stable form into the bloodstream during the course of the disease. Accordingly, Liu et al [40] recently observed a good correlation between the levels of three lncRNAs (ANRIL, HIF1A-AS2 and UCA1) in plasma and tumor tissues of patients with TNBC. Additionally, our group recently identified three circulating lncRNAs (GAS5, ZFAS1 and RMRP) that were found to be deregulated in patients with advanced breast cancer [41].…”

Section: Lncrnas and Breast Cancermentioning

confidence: 96%

Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer

2018

View full text Add to dashboard Cite

Background Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/or HER2, as well as the degree of proliferative activity. Recent work has focused on improving our knowledge on the molecular mechanisms that underlie this complex disease. Most of the human genome is transcribed into RNAs that do not encode proteins. These noncoding RNAs may act as mediators in the regulation of gene expression. Based on their size and function, noncoding RNAs are classified into small noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs). LncRNAs have been found to play key roles in relevant biological processes, including breast cancer. As such, lncRNAs have been proposed as diagnostic and prognostic biomarkers, as predictive biomarkers and as putative therapeutic targets. Conclusions In this review, we discuss the potential application of lncRNAs for the monitoring and treatment of breast cancer. We conclude that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets. As such, tumor-specific lncRNAs may be instrumental for improving current breast cancer clinical practices.

show abstract

A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers

Cited by 63 publications

References 40 publications

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

The oncogenic potentials and diagnostic significance of long non‐coding RNA LINC00310 in breast cancer

Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer

Contact Info

Product

Resources

About